Kim Dueholm - Net Worth and Insider Trading

Kim Dueholm Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Kim Dueholm owns 1 companies in total, including Akebia Therapeutics Inc (AKBA) .

Click here to see the complete history of Kim Dueholm’s form 4 insider trades.

Insider Ownership Summary of Kim Dueholm

Ticker	Comapny	Transaction Date	Type of Owner
AKBA	Akebia Therapeutics Inc	2014-03-19	director

Kim Dueholm Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Kim Dueholm Ownership Network

Ownership Network List of Kim Dueholm

No Data

Ownership Network Relation of Kim Dueholm

Kim Dueholm Owned Company Details

What does Akebia Therapeutics Inc do?

Who are the key executives at Akebia Therapeutics Inc?

Kim Dueholm is the director of Akebia Therapeutics Inc. Other key executives at Akebia Therapeutics Inc include SVP & Chief Business Officer Michel Dahan , SVP & General Counsel & Sec. Nicole R. Hadas , and SVP & Chief Medical Officer Steven Keith Burke .

Akebia Therapeutics Inc (AKBA) Insider Trades Summary

Over the past 18 months, Kim Dueholm made no insider transaction in Akebia Therapeutics Inc (AKBA). Other recent insider transactions involving Akebia Therapeutics Inc (AKBA) include a net sale of 149,723 shares made by Michel Dahan , a net sale of 106,103 shares made by Steven Keith Burke , and a net sale of 88,587 shares made by Nicole R. Hadas .

In summary, during the past 3 months, insiders sold 0 shares of Akebia Therapeutics Inc (AKBA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 492,283 shares of Akebia Therapeutics Inc (AKBA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 492,283 shares.

Akebia Therapeutics Inc (AKBA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Akebia Therapeutics Inc Insider Transactions

No Available Data

Kim Dueholm Mailing Address

Above is the net worth, insider trading, and ownership report for Kim Dueholm. You might contact Kim Dueholm via mailing address: C/o Akebia Therapeutics, Inc., 245 First Street, Suite 1100, Cambridge Ma 02142.

Discussions on Kim Dueholm

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.